2012-09-03 20:02:09 -
Mechelen, Belgium; 3 September 2012 - Galapagos NV (Euronext: GLPG) announced
today that its Board of Directors created 530,140 warrants under a new warrant
plan for the benefit of employees, directors and independent consultants of the
Company and its subsidiaries.
On 3 September 2012, the Board of Directors of Galapagos approved the "Warrant
Plan 2012" within the framework of the authorized capital. Under this warrant
plan, 530,140 warrants were created, subject to acceptances.
The warrants created under Warrant Plan 2012 were offered on 3 September 2012,
mainly to employees of Galapagos and its subsidiaries and in secondary order to
its directors and consultants. The offer of warrants to directors has been pre-
approved by the Extraordinary
General Shareholders' Meeting held on 22
The warrants have an exercise term of eight years as of the date of the offer
and have an exercise price of €14.19 (the average closing price of the share on
Euronext Brussels during the thirty days preceding date of the offer). The
warrants are not transferable and can in principle not be exercised prior to the
end of the third calendar year after the calendar year in which they were
granted to the beneficiaries. Each warrant gives the right to subscribe to one
new Galapagos share. Should the warrants be exercised, Galapagos will apply for
the listing of the resulting new shares on a regulated stock market. The
warrants as such will not be listed on any stock market.
To date, Galapagos' total share capital amounts to €143,770,414.14; the total
number of securities conferring voting rights is 26,577,554, which is also the
total number of voting rights (the "denominator"), and all securities conferring
voting rights and all voting rights are of the same category. The total number
of rights (warrants) to subscribe to not yet issued securities conferring voting
rights is 3,696,502, which equals the total number of voting rights that may
result from the exercise of these warrants. Galapagos does not have any
convertible bonds or shares without voting rights outstanding.
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size clinical stage
biotechnology company specialized in the discovery and development of small
molecule and antibody therapies with novel modes-of-action. The Company is
progressing its JAK1 inhibitor GLPG0634, as well as one of the largest pipelines
in biotech, with four programs in development and over 30 discovery programs.
The Galapagos Group has over 800 employees and operates facilities in six
countries, with global headquarters in Mechelen, Belgium. More info at:
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes,"
"expects," "intends," "plans," "seeks,"
"estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE